Parkinson’s Disease: A World of Promise. Sarah Click Dr. Julie Gurwell Spring 2006. Background . Movement disorder Affects over 1 million people usually middle aged 2 nd most common ND disorder behind AD. Background cont’d. Progression due to loss of DA neurons in the brain
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Dr. Julie Gurwell
Standard criteria to diagnose is 2 of these
Decrease in balance performance and gait
Hypophonia (motor)Background cont’d
Drapier et al. studied 27 patients that underwent bilateral STN DBS between 1999 and 2002
19 men and 8 women took part in the study
Goal was to determine quality of life before and after surgery
Age ≤ 75
Drug induced dyskinesias
Marked cerebral atrophy on MRI
Major depression before surgerySTN DBS
Krause et al studied 27 patients that underwent bilateral STN DBS in 1997
Age range from 44-72
Symptom duration 7-25 yrs
Mean follow-up time ~29.8 months (range 23-55)
Goal similar to previous study
Patients with advanced PD
Severe pharmacological side effects
None listedSTN DBS cont’d
Note: most adverse events were related to amplitude and could be fixed if the IPG was turned down
1. Burch D, Sheerin F. Parkinson's disease. Lancet 2005;365:622-7.
2. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 2004;19:845-54.
3. Dewey RB, Jr. Management of motor complications in Parkinson's disease. Neurology 2004;62:S3-7.
4. Filali M, Hutchison WD, Palter VN, Lozano AM, Dostrovsky JO. Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus. Exp Brain Res 2004;156:274-81.
5. Ferreira JJ, Rascol O. Drug-related sleep disturbances and Parkinson's disease: effects of dopaminergic antiparkinsonian drugs on sleep and wakefulness. European J Neurol 2000;7(Suppl. 4):26-35.
6. Nilsson MH, Tornqvist AL, Rehncrona S. Deep-brain stimulation in the subthalamic nuclei improves balance performance in patients with Parkinson's disease, when tested without anti-parkinsonian medication. Acta Neurol Scand 2005;111:301-8.
7. Hindmarch, I. Possible causes of daytime sleepiness with particular regard to patients with Parkinson's disease. European J Neurol 2000; 7(Supp. 4):9-14.
8. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21:687-709.
9. Straits-Troster K, Fields JA, Wilkinson SB, et al. Health-related quality of life in Parkinson's disease after pallidotomy and deep brain stimulation. Brain Cogn 2000;42:399-416.
10. Yoshor D, Hamilton WJ, Ondo W, Jankovic J, Grossman RG. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery 2001;48:818-24; discussion 824-6.
11. Breit S, Schulz JB, Benabid AL. Deep brain stimulation. Cell Tissue Res 2004;318:275-88.
12. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004;62:201-7.
13. Krause M, Fogel W, Mayer P, Kloss M, Tronnier V. Chronic inhibition of the subthalamic nucleus in Parkinson's disease. J Neurol Sci 2004;219:119-24.
14. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002;59:1427-9.
15. Drapier S, Raoul S, Drapier D, et al. Only physical aspects of quality of life are significantly improved by bilateral subthalamic stimulation in Parkinson's disease. J Neurol 2005;252:583-8.
16. Kulisevsky J, Berthier ML, Gironell A, Pascual-Sedano B, Molet J, Pares P. Mania following deep brain stimulation for Parkinson's disease. Neurology 2002;59:1421-4.
17. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry 2005;76:34-9.
18. Burkhard PR, Vingerhoets FJ, Berney A, Bogousslavsky J, Villemure JG, Ghika J. Suicide after successful deep brain stimulation for movement disorders. Neurology 2004;63:2170-2.
19. Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 2000;123 ( Pt 10):2091-108.
20. Alegret M, Junque C, Valldeoriola F, et al. Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol 2001;58:1223-7.
21. Pillon B, Ardouin C, Damier P, et al. Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology 2000;55:411-8.